620 related articles for article (PubMed ID: 34387870)
1. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
2. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment.
Lin Y; Li B; Yang X; Cai Q; Liu W; Tian M; Luo H; Yin W; Song Y; Shi Y; He R
Neoplasia; 2019 Dec; 21(12):1133-1142. PubMed ID: 31759251
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
[TBL] [Abstract][Full Text] [Related]
4. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
Ravichandra A; Bhattacharjee S; Affò S
Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis.
Nallasamy P; Nimmakayala RK; Karmakar S; Leon F; Seshacharyulu P; Lakshmanan I; Rachagani S; Mallya K; Zhang C; Ly QP; Myers MS; Josh L; Grabow CE; Gautam SK; Kumar S; Lele SM; Jain M; Batra SK; Ponnusamy MP
Gastroenterology; 2021 Dec; 161(6):1998-2013.e7. PubMed ID: 34418441
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells.
Thongchot S; Ferraresi A; Vidoni C; Loilome W; Yongvanit P; Namwat N; Isidoro C
Cancer Lett; 2018 Aug; 430():160-171. PubMed ID: 29802929
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.
Yamanaka T; Harimoto N; Yokobori T; Muranushi R; Hoshino K; Hagiwara K; Gantumur D; Handa T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Shirabe K
Br J Cancer; 2020 Mar; 122(7):986-994. PubMed ID: 32015511
[TBL] [Abstract][Full Text] [Related]
10. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.
Chen J; Tang Y; Qin D; Yu X; Tong H; Tang C; Tang Z
J Transl Med; 2023 Dec; 21(1):923. PubMed ID: 38124204
[TBL] [Abstract][Full Text] [Related]
11. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
12. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.
Affo S; Nair A; Brundu F; Ravichandra A; Bhattacharjee S; Matsuda M; Chin L; Filliol A; Wen W; Song X; Decker A; Worley J; Caviglia JM; Yu L; Yin D; Saito Y; Savage T; Wells RG; Mack M; Zender L; Arpaia N; Remotti HE; Rabadan R; Sims P; Leblond AL; Weber A; Riener MO; Stockwell BR; Gaublomme J; Llovet JM; Kalluri R; Michalopoulos GK; Seki E; Sia D; Chen X; Califano A; Schwabe RF
Cancer Cell; 2021 Jun; 39(6):866-882.e11. PubMed ID: 33930309
[TBL] [Abstract][Full Text] [Related]
13. Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.
Sun L; Wang Y; Wang L; Yao B; Chen T; Li Q; Liu Z; Liu R; Niu Y; Song T; Liu Q; Tu K
J Exp Clin Cancer Res; 2019 Apr; 38(1):170. PubMed ID: 30999932
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L
J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841
[TBL] [Abstract][Full Text] [Related]
15. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
[TBL] [Abstract][Full Text] [Related]
16. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Aoki S; Inoue K; Klein S; Halvorsen S; Chen J; Matsui A; Nikmaneshi MR; Kitahara S; Hato T; Chen X; Kawakubo K; Nia HT; Chen I; Schanne DH; Mamessier E; Shigeta K; Kikuchi H; Ramjiawan RR; Schmidt TC; Iwasaki M; Yau T; Hong TS; Quaas A; Plum PS; Dima S; Popescu I; Bardeesy N; Munn LL; Borad MJ; Sassi S; Jain RK; Zhu AX; Duda DG
Gut; 2022 Jan; 71(1):185-193. PubMed ID: 33431577
[TBL] [Abstract][Full Text] [Related]
17. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.
Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y
Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma.
Xiang H; Ramil CP; Hai J; Zhang C; Wang H; Watkins AA; Afshar R; Georgiev P; Sze MA; Song XS; Curran PJ; Cheng M; Miller JR; Sun D; Loboda A; Jia Y; Moy LY; Chi A; Brandish PE
Cancer Immunol Res; 2020 Apr; 8(4):436-450. PubMed ID: 32075803
[TBL] [Abstract][Full Text] [Related]
20. Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma.
Loeuillard EJ; Li B; Stumpf HE; Yang J; Willhite JR; Tomlinson JL; Rohakhtar FR; Simon VA; Graham RP; Smoot RL; Dong H; Ilyas SI
Cell Mol Gastroenterol Hepatol; 2024; 17(5):853-876. PubMed ID: 38219900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
